November 22, 2026

London Globe

London News

MHRA Unveils Innovative Programme to Address Evidence Gaps in Women’s Health

MHRA Unveils Innovative Programme to Address Evidence Gaps in Women's Health

Women are poised to benefit from improved evidence regarding medicines and medical devices, particularly concerning how their associated risks and benefits may vary for women. This initiative was launched today by the Medicines and Healthcare products Regulatory Agency (MHRA).

Despite constituting 51% of the population, women have historically encountered significant gaps in research and treatment across various health conditions. They have often been underrepresented in clinical research, which has limited the available evidence on medicines and medical devices during pregnancy and in relation to reproductive health. Furthermore, there remain unmet needs for conditions that specifically affect women, as well as those that manifest differently or disproportionately in women.

An analysis conducted by the MHRA of all 4,616 clinical trial applications submitted in the UK between 2019 and 2023 has underscored persistent gaps in representation. Pregnant women were included in merely 1.1% of trials, while breastfeeding women accounted for only 0.6%.

A Programme to Address Health Disparities

The Women’s Health Programme aims to tackle these challenges and investigate how enhanced data and scientific advancements can better reflect the specific needs of women.

The Women’s Health Minister, Baroness Gillian Merron, emphasised the importance of this initiative:

“For too long, women’s health has been overlooked. Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it. This new programme is a welcome step. Together with our renewed Women’s Health Strategy, it will mean better evidence, better treatments, and a health system that listens to women and works for them.”

See also  Exciting Launch of Innovative Digital Patent Services for Creators and Innovators

Lawrence Tallon, Chief Executive of the MHRA, remarked:

“Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a significant opportunity. Better evidence can help us understand where important differences exist, support researchers and innovators, and create opportunities for healthcare that is better tailored to women’s needs.”

Given the complexity of medicines and medical devices, factors such as biology, age, pregnancy, and other health conditions can influence how individuals respond to them. The programme seeks to unite patients, researchers, healthcare professionals, and industry stakeholders to bolster the available evidence while upholding rigorous standards of safety, quality, and effectiveness.

Innovation in Women’s Health

Women’s health is also a critical area for innovation. The UK’s rapidly expanding FemTech sector has achieved an annual turnover of nearly £300 million, with technologies being developed in areas ranging from reproductive health to long-term conditions and healthy ageing.

By collaborating with researchers and innovators from the outset and improving the evidence regarding how the benefits and risks of medicines may differ for women, the MHRA aims to cultivate an environment where promising new products can be developed and made available to patients more swiftly.

Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, stated:

“We welcome the MHRA’s Women’s Health Programme and its ambition to strengthen the evidence base for women’s health. Ensuring that individuals who are underrepresented in research are considered and included in clinical trials is crucial for generating evidence that is relevant to the populations who will ultimately use new medicines and treatments.”

See also  UK Galleries Called to Action to Preserve Unique Renaissance Masterpiece

“Our joint guidance with the MHRA on developing an Inclusion and Diversity Plan provides a practical framework to assist researchers in considering, from the earliest stages of study design, how their participant population can better reflect those who may benefit from the research. This will ensure that women, girls, and those who are pregnant or breastfeeding are not overlooked in research pertinent to them.”

The guidance, along with the MHRA’s Women’s Health Programme, will contribute to significant efforts across the health and social care research sector to enhance the inclusivity and representativeness of studies, thereby ensuring that the evidence generated more accurately reflects diverse populations and supports initiatives aimed at reducing health inequalities.

Support from Industry Leaders

Michelle Riddalls OBE, Chief Executive of PAGB, The Consumer Healthcare Association, commented:

“It is encouraging to see the MHRA’s new Women’s Health Programme prioritising the closure of longstanding evidence gaps while fostering responsible innovation. Better evidence can empower women to make more informed choices and create opportunities to increase access to appropriate treatments through the reclassification of medicines, enabling more women to manage their health through self-care.”

“Recent reclassifications of low-dose Estradiol vaginal products and Estriol cream have significantly improved access to Hormone Replacement Therapy (HRT) for thousands of women, demonstrating positive examples of providing women with greater choice and more convenient access to treatments.”

The programme has been shaped with input from patients, including contributions from the MHRA’s Patient and Public Community and focus groups conducted by the Patients Association. It represents the initial phase of a broader MHRA initiative to address health inequalities, as outlined in the recently launched 2030 Strategy.

See also  Minister Urges Israel to Increase Humanitarian Aid to Gaza During Landmark Regional Visit

A Broader Government Initiative

The Women’s Health Programme stands as the MHRA’s regulatory contribution to the government’s overarching aim of enhancing women’s health through the renewed Women’s Health Strategy for England and corresponding efforts in Scotland, Wales, and Northern Ireland.

This announcement will be made during the inaugural DIA-MHRA Global Summit, taking place in London on 16–17 November 2026, as part of London Life Sciences Week. Hosted jointly by the MHRA and the Drug Information Association (DIA), the Summit convenes international regulators, industry leaders, researchers, healthcare professionals, and patient representatives to explore how global collaboration can foster innovation and expedite its delivery to patients.

The MHRA is committed to regulating all medicines and medical devices in the UK, ensuring they are both effective and safe. All operations are grounded in robust and fact-based assessments to ensure that the benefits outweigh any associated risks.

The MHRA is an executive agency of the Department of Health and Social Care.